| Name | Title | Contact Details |
|---|
Our mission is to provide workplace and occupancy management software that is easy to use, quick to implement, and provides ongoing value for your entire organization. Our subscription plans are simple, affordable, and include full access to our growing features list. We believe that organizations of all sizes should have access to powerful tools to get the most out of their spaces and keep their employees happy and healthy. By combining executive-level analytics with an intuitive, cloud-based platform, Maptician drives measurable bottom-line savings, more informed space planning against more accurate data, and an improved employee experience.
Troicom is a Tustin, CA-based company in the Business Services sector.
Amerex was formed in 1978 in New York as a broker of domestic petroleum products. In 1980 it began to broker international crude oil, and in 1981 opened offices in London and Tokyo to better serve those markets. In 1985, to further concentrate on the
Arnold Katz Photography is a New York, NY-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.